Dendritic cells and dinitrochlorobenzene (DNCB): a new treatment approach to AIDS.
Recent studies suggest that antigen-presenting cells (dendritic cells) may play a key role in the pathogenesis of human immunodeficiency virus (HIV) infection. This observation makes new immunomodulatory treatment strategies desirable. Topical dinitrochlorobenzene (DNCB) is discussed as a possible treatment modality in the context of its proven therapeutic uses and its immunomodulatory effect on dendritic cells. DNCB may be a safe, inexpensive, and widely available treatment option for HIV disease.
Stricker
R B
RB
Children's Hospital of San Francisco, CA 94118.
Elswood
B F
BF
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000191:economics / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology*; D004137:Dinitrochlorobenzene / Q000627:therapeutic use*; D006678:HIV / Q000187:drug effects / Q000254:growth & development; D006801:Humans; D007801:Langerhans Cells / Q000276:immunology
D004137:Dinitrochlorobenzene